BioMarin Ends VOXZOGO Development in Noonan Syndrome

Company BioMarin Pharmaceutical Event Type Portfolio Decision (Program Discontinuation) Modality C-Type Natriuretic Peptide Analog Asset VOXZOGO (vosoritide) Target FGFR3 Signaling Pathway Disease Area Noonan Syndrome (discontinued expansion; approved use remains achondroplasia) Summary BioMarin discontinued development of VOXZOGO in children with Noonan syndrome after assessing study…